Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-438 (Vonoprazan) in Healthy Men
NCT02141698Phase 1Completed
- Sponsor
- Takeda
- Start
- Oct 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of vonoprazan in gastroesophageal reflux disease (GERD), gastric ulcer and duodenal ulcer (14 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration at Day 1, Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity at Day 1 and 8 more. Started Oct 2007; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on NCT02141698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141698.